当前位置： SCI文献检索 > CLINICAL AND EXPERIMENTAL IMMUNOLOGY期刊下所有文献 > T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study.

T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study.

Abstract：

:Myelin-reactive T cells are considered to play an essential role in the pathogenesis of multiple sclerosis (MS), an autoimmune disease of the central nervous system. We have previously studied the effects of T cell vaccination (TCV), a procedure by which MS patients are immunized with attenuated autologous myelin basic protein (MBP)-reactive T cell clones. Because several myelin antigens are described as potential autoantigens for MS, T cell vaccines incorporating a broad panel of antimyelin reactivities may have therapeutic effects. Previous reports have shown an accumulation of activated T cells recognizing multiple myelin antigens in the cerebrospinal fluid (CSF) of MS patients. We conducted a pilot clinical trial of TCV with activated CD4+ T cells derived from CSF in five MS patients (four RR, one CP) to study safety, feasibility and immune effects of TCV. CSF lymphocytes were cultured in the presence of rIL-2 and depleted for CD8 cells. After 5-8 weeks CSF T cell lines (TCL) were almost pure TCR alpha beta+CD4+ cells of the Th1/Th0 type. The TCL showed reactivity to MBP, MOG and/or PLP as tested by Elispot and had a restricted clonality. Three immunizations with irradiated CSF vaccines (10 million cells) were administered with an interval of 2 months. The vaccinations were tolerated well and no toxicity or adverse effects were reported. The data from this small open-label study cannot be used to support efficacy. However, all patients remained clinically stable or had reduced EDSS with no relapses during or after the treatment. Proliferative responses against the CSF vaccine were observed in 3/5 patients. Anti-ergotypic responses were observed in all patients. Anti-MBP/PLP/MOG reactivities remained low or were reduced in all patients. Based on these encouraging results, we recently initiated a double-blind placebo-controlled trial with 60 MS patients to study the effects of TCV with CSF-derived vaccines in early RR MS patients.

journal_name

Clin Exp Immunol

journal_title

Clinical and experimental immunology

authors

Van der Aa A,Hellings N,Medaer R,Gelin G,Palmers Y,Raus J,Stinissen P

doi

10.1046/j.1365-2249.2003.02019.x

subject

Has Abstract

pub_date

2003-01-01 00:00:00

pages

155-68

issue

eissn

0009-9104

issn

1365-2249

pii

2019

journal_volume

131

pub_type

杂志文章

在线工具

T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study.